Physician profile
Nathaniel Brownlow
NPI 1447225891
$3,911.28
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $374 · 2021: $397 · 2022: $1,147 · 2023: $1,211 · 2024: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,787.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,504.26 | 2019-2024 | Epclusa, Descovy |
| Astrazeneca Pharmaceuticals LP | $541.30 | 2021-2024 | Breztri, Airsupra, Fasenra |
| Viiv Healthcare Company | $448.99 | 2022-2024 | Apretude |
| Bayer Healthcare Pharmaceuticals INC. | $437.87 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $328.83 | 2019-2020 | |
| Exact Sciences Corporation | $137.47 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $125.00 | 2023 | Nucala |
| Biogen, INC. | $86.35 | 2021-2022 | |
| Lilly USA, LLC | $81.79 | 2022-2023 | Jardiance, Emgality |
| Idorsia Pharmaceuticals US INC | $71.29 | 2022-2023 | Quviviq |
| Abbvie INC. | $52.43 | 2022-2023 | Mavyret |
| Hologic Sales and Service, LLC | $43.91 | 2022-2023 | Aptima |
| Neurocrine Biosciences, INC. | $24.18 | 2020 | |
| Avion Pharmaceuticals | $14.67 | 2022 | |
| Genentech USA, INC. | $12.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Brownlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.